» Articles » PMID: 9275020

Murine P-glycoprotein on Stromal Vessels Mediates Multidrug Resistance in Intracerebral Human Glioma Xenografts

Overview
Journal Br J Cancer
Specialty Oncology
Date 1997 Jan 1
PMID 9275020
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Human glioma usually shows intrinsic multidrug resistance because of the blood-brain barrier (BBB), in which membrane-associated P-glycoprotein (P-gp), encoded by the human multidrug resistance gene MDR1, plays a role. We studied drug sensitivity to vincristine (VCR), doxorubicin (DOX) and nimustine (ACNU) in both intracerebrally and subcutaneously xenotransplanted human glioma. We examined the levels of MDR1 and murine mdr3 gene expression in the xenografts by reverse transcriptase polymerase chain reaction and the localization of P-gp by immunohistochemistry. Six of seven subcutaneously transplanted xenografts (scX) were sensitive to the above three drugs. In contrast, all three intracerebrally transplanted human glioma xenografts (icX) were resistant to P-gp-mediated drugs VCR and DOX, but were sensitive to the non-P-gp-mediated drug ACNU. Neither icX nor scX showed any MDR1 expression. Intracerebrally transplanted human glioma xenografts showed an increased level of murine mdr3 gene expression, whereas scX showed only faint expression. The localization of P-gp was limited to the stromal vessels in icX by immunohistochemistry, whereas scX expressed no P-gp. Our findings suggest that the P-gp expressed on the stromal vessels in icX is a major contributing factor to multidrug resistance in human glioma in vivo.

Citing Articles

An Insight into Molecular Targets of Breast Cancer Brain Metastasis.

Kaleem M, Dalhat M, Azmi L, Asar T, Ahmad W, Alghanmi M Int J Mol Sci. 2022; 23(19).

PMID: 36232989 PMC: 9569595. DOI: 10.3390/ijms231911687.


Novel Treatment Approaches for Brain Tumour from a Blood-Brain Barrier Perspective.

Wu S, Tsai C, Hynynen K Handb Exp Pharmacol. 2021; 273:351-364.

PMID: 33454856 DOI: 10.1007/164_2020_408.


Brain Delivery of Single-Domain Antibodies: A Focus on VHH and VNAR.

Pothin E, Lesuisse D, Lafaye P Pharmaceutics. 2020; 12(10).

PMID: 33007904 PMC: 7601373. DOI: 10.3390/pharmaceutics12100937.


ABC Transporters at the Blood-Brain Interfaces, Their Study Models, and Drug Delivery Implications in Gliomas.

Gomez-Zepeda D, Taghi M, Scherrmann J, Decleves X, Menet M Pharmaceutics. 2019; 12(1).

PMID: 31878061 PMC: 7022905. DOI: 10.3390/pharmaceutics12010020.


A unique carrier for delivery of therapeutic compounds beyond the blood-brain barrier.

Karkan D, Pfeifer C, Vitalis T, Arthur G, Ujiie M, Chen Q PLoS One. 2008; 3(6):e2469.

PMID: 18575595 PMC: 2424243. DOI: 10.1371/journal.pone.0002469.


References
1.
Parnes J, Seidman J . Structure of wild-type and mutant mouse beta 2-microglobulin genes. Cell. 1982; 29(2):661-9. DOI: 10.1016/0092-8674(82)90182-9. View

2.
Abe Y, Ohnishi Y, Yoshimura M, Ota E, Ozeki Y, Oshika Y . P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo. Br J Cancer. 1996; 74(12):1929-34. PMC: 2074809. DOI: 10.1038/bjc.1996.655. View

3.
Gros P, Ben Neriah Y, Croop J, Housman D . Isolation and expression of a complementary DNA that confers multidrug resistance. Nature. 1986; 323(6090):728-31. DOI: 10.1038/323728a0. View

4.
Thiebaut F, Tsuruo T, Hamada H, Gottesman M, Pastan I, Willingham M . Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A. 1987; 84(21):7735-8. PMC: 299375. DOI: 10.1073/pnas.84.21.7735. View

5.
KORNBLITH P, Walker M . Chemotherapy for malignant gliomas. J Neurosurg. 1988; 68(1):1-17. DOI: 10.3171/jns.1988.68.1.0001. View